Catch-Up Immuniza Ti On Schedule For Individuals 4 Months Through 18 Years Old Page 2

ADVERTISEMENT

1. Hepati ti s B vaccine (HepB).
6. Inacti vated poliovirus vaccine (IPV).
• Administer the 3-dose series to those not previously vaccinated.
• The fi nal dose in the series should be administered on or aft er the fourth birthday and at least 6
• The minimum age for the third dose of HepB is 24 weeks.
months following the previous dose.
• A 2-dose series (separated by at least 4 months) of adult formulati on Recombivax HB® is licensed for
• A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6
children aged 11 through 15 years.
months following the previous dose.
• In the fi rst 6 months of life, minimum age and minimum intervals are only recommended if the person
2. Rotavirus vaccine (RV).
is at risk for imminent exposure to circulati ng poliovirus (i.e., travel to a polio-endemic region or during
• The maximum age for the fi rst dose is 14 weeks 6 days. Vaccinati on should not be initi ated for infants
an outbreak).
aged 15 weeks 0 days or older.
• The maximum age for the fi nal dose in the series is 8 months 0 days.
7. Measles, mumps, and rubella vaccine (MMR).
• If Rotarix® was administered for the fi rst and second doses, a third dose is not indicated.
• Administer the second dose routi nely at age 4 through 6 years. The minimum interval between the 2
doses of MMR is 4 weeks.
3. Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).
• The fi ft h dose is not necessary if the fourth dose was administered at age 4 years or older.
8. Varicella vaccine.
• Administer the second dose routi nely at age 4 through 6 years.
4. Haemophilus infl uenzae type b conjugate vaccine (Hib).
• If the second dose was administered at least 4 weeks aft er the fi rst dose, it can be accepted as valid.
• 1 dose of Hib vaccine should be considered for unvaccinated persons aged 5 years or older who have
sickle cell disease, leukemia, or HIV infecti on, or who have had a splenectomy.
9. Hepati ti s A vaccine (HepA).
• If the fi rst 2 doses were PRP-OMP (PedvaxHIB or Comvax), and administered at age 11 months or
• HepA is recommended for children aged older than age 23 months who live in areas where vaccinati on
younger, the third (and fi nal) dose should be administered at age 12 through 15 months and at least 8
programs target older children, or who are at increased risk for infecti on, or for whom immunity
weeks aft er the second dose.
against Hepati ti s A is desired.
• If the fi rst dose was administered at age 7 through 11 months, administer the second dose at least 4
10. Tetanus and diphtheria toxoids vaccine (Td) and tetanus and diphtheria toxoids and acellular pertussis
weeks later and a fi nal dose at age 12 through 15 months.
vaccine (Tdap).
5. Pneumococcal vaccine.
• Doses of DTaP are counted as part of the Td/Tdap series.
• Administer 1 dose of 13-valent pneumococcal conjugate vaccine (PCV13) to all healthy children aged 24
• Tdap should be substi tuted for a single dose of Td in the catch-up series for children aged 7 through 10
through 59 months with any incomplete PCV schedule (PCV7 or PCV13).
years or as a booster for children aged 11 through 18 years; use Td for other doses.
• For children aged 24 through 71 months with underlying medical conditi ons, administer 1 dose of
11. Human papillomavirus vaccine (HPV).
PCV13 if 3 doses of PCV were received previously or administer 2 doses of PCV13 at least 8 weeks apart
• Administer the series to females at age 13 through 18 years if not previously vaccinated or have not
if fewer than 3 doses of PCV were received previously.
completed the vaccine series.
• A single dose of PCV13 is recommended for certain children with underlying medical conditi ons through
• Quadrivalent HPV vaccine (HPV4) may be administered in a 3-dose series to males aged 9 through 18
18 years of age. See age-specifi c schedules for details.
years to reduce their likelihood of genital warts.
• Administer pneumococcal polysaccharide vaccine (PPSV) to children aged 2 years or older with certain
• Use recommended routi ne dosing intervals for series catch-up (i.e., the second and third doses should
underlying medical conditi ons, including a cochlear implant, at least 8 weeks aft er the last dose of
be administered at 1 to 2 and 6 months aft er the fi rst dose). The minimum interval between the fi rst
PCV. A single revaccinati on should be administered aft er 5 years to children with functi onal or anatomic
and second doses is 4 weeks. The minimum interval between the second and third doses is 12 weeks,
asplenia or an immunocompromising conditi on. See MMWR 2010; 59(No. RR-11).
and the third dose should be administered at least 24 weeks aft er the fi rst dose.
Informati on about reporti ng reacti ons aft er immunizati on is available at or at 800.822.7967. Suspected cases of vaccine-preventable diseases should be reported to the state or local health
department. Additi onal informati on, including precauti ons and contraindicati ons for immunizati on, is available from the Nati onal Center for Immunizati on and Respiratory Diseases at or
at 800.232.4636 (800.CDC.INFO).
U.S. Department of Health and Human Services / Centers for Disease Control and Preventi on
Informati on provided by the Missouri Department of Health and Senior Services’ Bureau of Immunizati on Assessment and Assurance, 573.751.6124, March 2011

ADVERTISEMENT

00 votes

Related Articles

Related forms

Related Categories

Parent category: Medical
Go
Page of 2